Stereotaxis to acquire Robocath in landmark robotic surgery integration
Compartilhar
Stereotaxis (NYSE:STXS), a pioneer in innovative robotic technologies for the treatment of arrhythmias and endovascular disease, announced today that it has entered into a definitive agreement to acquire Robocath.
